Scholarlink

<p>The current study was designed to assess asiaticoside's therapeutic efficiency against diabetic dyslipidemia and oxidative stress in the liver induced by streptozotocin and nicotinamide. Asiaticoside (50 and 100&#xa0;mg/kg body weight) was orally administered to diabetic rats for 45&#xa0;days and its effect on the hyperglycemic markers, serum and liver lipid profiles, as well as lipid metabolism enzymes and their corresponding mRNA expressions were examined. In addition, we also examined the asiaticoside effect on hepatic oxidative stress and hepatic indigenous antioxidant status. The present study's findings demonstrated that administering asiaticoside to diabetic rats reduced their blood glucose levels while simultaneously raising their insulin levels. Furthermore, asiaticoside administration decreased liver lipid content and increased the activities and corresponding mRNA expressions of PPAR-α, PPAR-γ, lipoprotein lipase and lecithin-cholesterol acyltransferase, while suppressing the activities of SREBP-1c, HMG-CoA reductase and Fatty acid synthase. Furthermore, asiaticoside potentiated the reduced glutathione content and increased the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione <i>S</i>-transferase, and up-regulated the mRNA expression of Nrf-2, superoxide dismutase, glutathione peroxidase, and glutathione <i>S</i>-transferase. In summary, the study results emphasize that asiaticoside successfully inhibits fatty acid synthesis and increases fatty acid catabolism and their mobilization, as well as attenuates oxidative stress through regulation of the PPAR-α/γ and SREBP-1c axis and activation of the Nrf-2 signaling pathway.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Asiaticoside Attenuates Hepatic Lipid Metabolic Abnormalities and Oxidative Stress Via Regulation of PPAR-α/γ and SREBP-1c Axis and Activation of Nrf-2 Pathway in Diabetic Rats

  • 期刊论文

  • 发表日期：

    2025年12月8日

查看全文
  • Prathap Balasubramaniyan,
  • Sathyanarayanan Varadarajan,
  • Subashree Prathap

摘要

The current study was designed to assess asiaticoside's therapeutic efficiency against diabetic dyslipidemia and oxidative stress in the liver induced by streptozotocin and nicotinamide. Asiaticoside (50 and 100 mg/kg body weight) was orally administered to diabetic rats for 45 days and its effect on the hyperglycemic markers, serum and liver lipid profiles, as well as lipid metabolism enzymes and their corresponding mRNA expressions were examined. In addition, we also examined the asiaticoside effect on hepatic oxidative stress and hepatic indigenous antioxidant status. The present study's findings demonstrated that administering asiaticoside to diabetic rats reduced their blood glucose levels while simultaneously raising their insulin levels. Furthermore, asiaticoside administration decreased liver lipid content and increased the activities and corresponding mRNA expressions of PPAR-α, PPAR-γ, lipoprotein lipase and lecithin-cholesterol acyltransferase, while suppressing the activities of SREBP-1c, HMG-CoA reductase and Fatty acid synthase. Furthermore, asiaticoside potentiated the reduced glutathione content and increased the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione S-transferase, and up-regulated the mRNA expression of Nrf-2, superoxide dismutase, glutathione peroxidase, and glutathione S-transferase. In summary, the study results emphasize that asiaticoside successfully inhibits fatty acid synthesis and increases fatty acid catabolism and their mobilization, as well as attenuates oxidative stress through regulation of the PPAR-α/γ and SREBP-1c axis and activation of the Nrf-2 signaling pathway.

Graphical Abstract